Latest stories

  • in

    Topical Lovastatin new primary treatment option for patients of Disseminated Superficial Actinic Porokeratosis

    Topical Lovastatin new primary treatment option for patients of Disseminated Superficial Actinic Porokeratosis

    A new study found that there were no significant benefits in clinical improvements in Disseminated superficial actinic porokeratosis (DSAP) after adding cholesterol 2% cream to 2% lovastatin instead of plain lovastatin alone. The clinical improvements were almost similar in both groups as per the study results that were published in the journal JAMA Dermatology.   Disseminated […] More

  • in

    Novel primary care model proves effective for patients with severe mental illness

    Novel primary care model proves effective for patients with severe mental illness

    Cardiometabolic health conditions – such as high blood pressure, diabetes, and heart attacks – are more common in American adults with serious mental illness than the general population. With 14.2 million adults living with a serious mental illness, this represents a major challenge that the United States healthcare system must face head-on. Over the past […] More

  • in

    Lupin gets USFDA nod for primary biliary cholangitis drug Obeticholic Acid

    Mumbai: Global pharma major, Lupin Limited, has announced that the company has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Obeticholic Acid Tablets, 5 mg and 10 mg. Obeticholic acid tablets are used for treating primary biliary cholangitis. Primary biliary cholangitis is an autoimmune disease […] More